Author(s)
Content
Video Abstract (AI generated) (01:36) Paper Preprint Supplemental FiguresTwo proteases produced by the SARS-CoV-2 virus, Mpro and PLpro, are essential for viral replication and have become the focus of drug development programs for treatment of COVID-19. We screened a highly focused library of compounds containing covalent warheads designed to target cysteine proteases to identify new lead scaffolds for both Mpro and PLpro proteases. These efforts identified a small number of hits for the Mpro protease and no viable hits for the PLpro protease. Of the Mpro hits identified as inhibitors of the purified recombinant protease, only two compounds inhibited viral infectivity in cellular infection assays. However, we observed a substantial drop in antiviral potency upon expression of TMPRSS2, a transmembrane serine protease that acts in an alternative viral entry pathway to the lysosomal cathepsins. This loss of potency is explained by the fact that our lead Mpro inhibitors are also potent inhibitors of host cell cysteine cathepsins. To determine if this is a general property of Mpro inhibitors, we evaluated several recently reported compounds and found that they are also effective inhibitors of purified human cathepsin L and B and showed similar loss in activity in cells expressing TMPRSS2. Our results highlight the challenges of targeting Mpro and PLpro proteases and demonstrate the need to carefully assess selectivity of SARS-CoV-2 protease inhibitors to prevent clinical advancement of compounds that function through inhibition of a redundant viral entry pathway.
More Projects
Loren Frank
13 views • 2 years ago
Global Immunotalks
390 views • 3 years ago
Laurel Yohe
2 views • 2 years ago
Global Immunotalks
130 views • 3 years ago
Jignesh H. Parmar
0 views • 2 years ago
Winston A. Haynes
0 views • 2 years ago
Noam Mazor
0 views • 2 years ago
Global Immunotalks
182 views • 3 years ago
Cem Yuksel
345 views • 2 years ago
Oscar Gonzalez-Recio
3 views • 2 years ago
Please pick a style:
Mirko Cortese. (2021, Nov 5).Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19[Video]. Scitok. https://scitok.com/project/p/f7369dff
Steuten Kas. "Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19" Scitok, uploaded by Cortese Mirko, 5 Nov, 2021, https://scitok.com/project/pf7369dff
Mirko Cortese. "Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19" Scitok. (Nov 5, 2021). https://scitok.com/project/p/f7369dff
Mirko Cortese (Nov 5, 2021). Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 Scitok. https://scitok.com/project/p/f7369dff
Mirko Cortese. Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19[video]. 2021 Nov 5. https://scitok.com/project/p/f7369dff
@online{al2006link, title={ Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 }, author={ Cortese, Mirko }, organization={Scitok}, month={ Nov }, day={ 5 }, year={ 2021 }, url = {https://scitok.com/project/p/f7369dff}, }